Yang Jianxin, CEO of Cornerstone Pharmaceuticals, believes t...

Yang Jianxin, CEO of Cornerstone Pharmaceuticals, believes that the clinical value of Zegemei in first-line gastric cancer has been recognized. Due to the poor prognosis of patients with advanced gastric cancer, Professor Shen Lin of Peking University Cancer Hospital pointed out that the combination chemotherapy with Jiemei is of great significance in prolonging the survival of such patients, and may be their new treatment option.